.png)
June 4, 2026
Supporting Innovation in Friedrich Ataxia Clinical Research
Recently announced clinical results show positive data as part of the ongoing PHASE1/2 RESTORE-FA trial
Register Your Interest
English
A skills-based board combines comprehensive experience in academic research, financial strategy, commercial development and biotechnology & pharmaceutical industries. Along with the specialised leadership team, this expertise drives Doherty Clinical Trials Ltd unique capabilities.
Recently announced clinical results show positive data as part of the ongoing PHASE1/2 RESTORE-FA trial
Doherty Clinical Trials Limited is proud to announce the commencement of the CHIVAS-M1 study (Controlled Human Infection for Vaccination Against Streptococcus pyogenes M1UK), which will help drive medical research and development of a vaccine against Streptococcus pyogenes, otherwise known as Strep A.
Senior Lab Manager, Vanessa Mollard represented Doherty Clinical Trials at the forum in Canberra
Dr Andrew Brockway's panel, 'Clinical Trials in Australia: Performance, Competitive Advantages, Challenges and Evolving Policy' at AusBiotech 2024
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}